HC Wainwright reaffirmed their buy rating on shares of Sol Gel Technologies (NASDAQ:SLGL) in a research note released on Tuesday morning, TipRanks reports. They currently have a $21.00 target price on the stock.
SLGL has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Sol Gel Technologies from a hold rating to a buy rating and set a $9.25 price target on the stock in a research report on Thursday, May 28th. ValuEngine upgraded shares of Sol Gel Technologies from a hold rating to a buy rating in a research report on Thursday, May 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Sol Gel Technologies currently has a consensus rating of Buy and a consensus price target of $22.05.
Shares of NASDAQ SLGL opened at $8.81 on Tuesday. The company has a market capitalization of $180.66 million, a P/E ratio of -6.88 and a beta of 1.60. Sol Gel Technologies has a 52-week low of $5.00 and a 52-week high of $21.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.51 and a current ratio of 9.51. The company’s 50 day moving average price is $8.17 and its 200-day moving average price is $9.67.
Sol Gel Technologies (NASDAQ:SLGL) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.05. The firm had revenue of $3.47 million for the quarter, compared to the consensus estimate of $3.37 million. Sol Gel Technologies had a negative net margin of 129.88% and a negative return on equity of 44.64%. Analysts forecast that Sol Gel Technologies will post -1.45 earnings per share for the current year.
Several institutional investors have recently added to or reduced their stakes in SLGL. Phoenix Holdings Ltd. raised its holdings in Sol Gel Technologies by 3.6% during the fourth quarter. Phoenix Holdings Ltd. now owns 2,109,779 shares of the company’s stock worth $35,933,000 after buying an additional 72,682 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in Sol Gel Technologies by 32.7% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 43,885 shares of the company’s stock worth $310,000 after buying an additional 10,812 shares during the last quarter. Raymond James & Associates raised its holdings in Sol Gel Technologies by 18.8% during the first quarter. Raymond James & Associates now owns 41,586 shares of the company’s stock worth $294,000 after buying an additional 6,581 shares during the last quarter. Steward Partners Investment Advisory LLC raised its holdings in Sol Gel Technologies by 20.9% during the first quarter. Steward Partners Investment Advisory LLC now owns 8,660 shares of the company’s stock worth $61,000 after buying an additional 1,500 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Sol Gel Technologies during the first quarter worth $117,000. Institutional investors own 34.07% of the company’s stock.
About Sol Gel Technologies
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
Recommended Story: Fundamental Analysis – How It Helps Investors
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.